---
title: "Eli Lilly&#39;s Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years"
date: "2025-02-07 20:59:38"
summary: "On Friday, Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz)."
categories:
  - "benzinga"
lang:
  - "en"
translations:
  - "en"
tags:
  - "benzinga"
menu: ""
thumbnail: "https://www.benzinga.com/files/images/story/2025/02/07/Indianapolis---Circa-November-2021-Eli-L.jpeg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

On Friday, Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).

[benzinga](https://www.benzinga.com/25/02/43558004/eli-lillys-recently-approved-inflammatory-bowel-disease-drug-shows-sustained-and-durable-treatment-at-two-years)
